The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been
evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver …

Purpose: As an approach to evaluate the expression pattern and status of activation of
signaling pathways in clinical specimens from head and neck squamous cell carcinoma …

While chemotherapy provides useful palliation, advanced lung cancer remains incurable
since those tumors that are initially sensitive to therapy rapidly develop acquired resistance …

Abstract Approximately 40–50% of glioblastomas (GBM) overexpress epidermal growth
factor receptor (EGFR). Erlotinib is a specific and potent EGFR tyrosine kinase inhibitor …

Purpose This study investigated whether sequential administration of erlotinib and
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …

Background Patients with non-small-cell lung cancer sometimes show a dramatic clinical
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …

The body of literature on the correlations between molecular assessments and patient
outcomes after treatment with epidermal growth factor receptor (EGFR) inhibitors continues …

Purpose: Signal transducers and activators of transcription 3 (Stat3), a member of the STAT
family of transcription factors, regulates multiple oncogenic pathways, including pathways …

Current estimates from the American Cancer Society and from the International Union
Against Cancer indicate that 12 million cases of cancer were diagnosed last year, with 7 …

The discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small
cell lung cancer (NSCLC) in 2004 heralded the era of molecular targeted therapy in NSCLC …